A study shows the larger gap of cancer patients between poor and rich countries

A recent study published in the journal “Kante”, attached to the American Cancer Society, has reviewed the major differences in the number of cancer deaths, the ability to tolerate the cost of treatment, in addition to the availability of medicine for this disease in different countries of the world. The study indicated that there are large gaps between high -income countries and other low -income countries, reflecting the fundamental challenges to achieve the necessary treatments. The study pointed out that cancer cases will see a noticeable increase in the coming decades, as the number of new infection cases in 2040 will reach approximately 28.4 million cases, and that low -income countries will affect this increase by this increase, while death rates will stabilize due to cancer in developed countries. The study showed that there are several factors contributing to high injuries and deaths in low -income countries compared to developed countries, including inequality in access to treatment, as patients in low -income countries experience more difficulties in achieving modern medicine such as immunotherapy, which can cost thousands of dollars annually compared to traditional chemical treatments. Cancer deaths and statistics have shown that 5 million people are currently dying in the world annually in the world, in countries with low income and medium income due to cancer, which make up about 10% of a total of 50 million deaths in these countries. Nevertheless, in most of these countries, cancer is not recognized as a healthy priority, as it is in places where children die from malaria and other infectious diseases, and they suffer from the effects of malnutrition, as women die during childbirth, and young people die from AIDS, cancer patients do not have adequate attention. The absence of early investigative programs leads to a delayed diagnosis of the disease in the early stages, which increases the problems of treatment and reduces the chances of recovery, and the continuation of carcinogenic risk factors, such as smoking, air pollution and exposure to harmful chemicals, is still distributed in some developing countries. According to the study, many countries with low income suffer from a lack of advanced medical facilities and specialized doctors, making cancer treatment more difficult. Low income countries also allocate a percentage less than their gross domestic product to care for cancer patients compared to rich countries, and despite this, they are sometimes forced to pay higher prices for the same basic medicine, contributing to the deepening of sanitary gaps between rich and poor countries. It is noteworthy that research related to cancer and optimal treatments often depends on studies conducted in high -income countries, which may not necessarily reflect the health needs and challenges in countries with low income and medium income. The study showed that this difference in research leads to a lack of accurate knowledge about how cancer affects poor areas, thereby negatively affecting the effectiveness of the treatments offered in these areas. Solutions to bridging gaps and researchers of cancer care suggests a set of solutions that can help reduce the growing gaps in caring for cancer patients around the world, including the use of ‘equivalent’ generic medicine and biomus molecules as an active alternative to reduce the cost of treatment, while also the quality of the treatment. Health insurance system that can contribute to improving access to treatments, especially in low countries in low countries and medium countries. The study emphasized that poor countries are needed to obtain financial support from international institutions and world health bodies to provide modern medicine at reasonable prices, in addition to improving the medical infrastructure in developing countries. The study suggested that international collaboration play an important role in tackling the challenges associated with the fight against cancer worldwide, especially in the field of supporting scientific research focusing on cancer in developing countries, in addition to exchanging advanced medical expertise and technologies between countries.